Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)

Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and neck. Chemotherapy remains standard in locoregionally advanced SCCHN, but the recent FDA’s approval of perioperative pembrolizumab is expected to reshape early-stage management. Targeted therapies are frequently prescribed to patients with recurrent or metastatic disease. The usual treatment algorithm starts with a PD-1 inhibitor (pembrolizumab [Keytruda]) for recurrent or metastatic disease, followed by an EGFR-targeting agent (cetuximab [Erbitux]) after progression. The expected approval of zanzalintinib (in combination with pembrolizumab) as a first-line treatment, along with the approval of petosemtamab (in combination with pembrolizumab), will significantly impact treatment in the recurrent and metastatic settings during the 2023-2033 forecast period. Ficlatuzumab (in combination with cetuximab), and petosemtamab in later-line treatment are expected to further reshape the treatment landscape for patients with recurrent and metastatic disease. The approval of toripalimab is setting a new treatment paradigm for nasopharyngeal SCCHN, with strong adoption anticipated. We anticipate that penpulimab will also gain approval and experience substantial uptake among these patients. Finally, the anticipated approval of nivolumab for locoregionally advanced disease is expected to follow a similar regulatory trajectory as pembrolizumab, further expanding early-stage treatment options.

Questions answered

• What is the anticipated evolution in the size of the drug-treatable SCCHN population from 2023 to 2033, and how will it impact the landscape of available treatment options?
• What are the key current therapies for locoregionally advanced and recurrent or metastatic SCCHN, and what are their positioning?
• How will drugs in late-phase development for SCCHN gain market and patient share?
• What are the driving forces and limitations influencing the SCCHN therapy market, and how do experts foresee these factors evolving over the 10-year forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.